Antithrombotic activity of the new antiplatelet compound Angipur: 615.273.53

Abstract

Summary. Background. The accumulated international and national experience shows that adequate assistance in the prevention and treatment of thrombotic complications leads to a reduction in mortality. One strategy to prevent these complications is the use of antiplatelet agents. Therefore, the search for new antithrombotic compounds is relevant. Objectives: study of antithrombotic activity of new heterocyclic xanthine derivative — compound angipur. Materials/Methods. Comparative study in vivo of antithrombotic activity of angipur and reference drugs eptifibatide and tirofiban was carried out in the model of pulmonary adrenaline-collagen thrombosis in mice. For this purpose, one control and three experimental groups were formed. A mixture of collagen and adrenaline solutions at dose of 0.5 mg/kg and 0.06 mg/kg, respectively, was used as a thrombotic agent, which in volume of 0.1 ml was injected into the tail vein of white outbred mice. All animals were subjected to autopsy for lungs histological evaluation for the presence of thrombus in arterial vessel wall and determination of thrombi parameters. Results. Angipur prevented 80% of animal deaths compared with 100% in the control group, and was 1.14 times superior to the reference drug tirofiban, but 1.25 times inferior to eptifibatide. Histological studies confirmed angipur antithrombotic activity, which reduced the relative and median area of thrombus on lung slice by 3.3 and 2.7 times respectively, compared with control. Conclusions. Angipur antithrombotic activity was revealed, associated with its ability to increase mice survival rate in the experiment with a single intravenous injection and exert a protective effect on animals with acute pulmonary thromboembolism, exceeding the comparison drugs eptifibatide and tirofiban.

References

1. Mozaffarian D., Benjamin E.J., Go A.S. et al. Heart disease and stroke statistics — 2016 update: a report from the American Heart Association. Circulation. 2016;133: e38-e360. DOI: 10.1161/ CIR.0000000000000350. 2. Reed G.W., Rossi J.E., Cannon C.P. Acute myocardial infarction. Lancet. 2017;389(10065):197–210. DOI: 10.1016/S0140–6736(16)30677–8. 3. Bogus S.K., Dukhanin A.S., Kucheryavenko A.F. et al. Pleyotropic antiaggregant effects of an innovative antiarrhythmic of class III SS-68, an indole derivative. Research Result: Pharmacology and Clinical Pharmacology. 2017;3(2):3–13. DOI: 10.18413/2313–8971–2017–3–2–3–13. 4. Kucheryavenko A.F., Anisimova V.A., Gaidukova K.A. et al. Antiplatelet activity of a new tricyclic derivative of 2,3,4,5-tetrahydro[1,3]diazepino[1,2-a]benzimidazole. Eksperimental’naya i klinicheskaya farmakologiya. 2016;79(5):29–32. (In Russ.). DOI: 10.30906/0869–2092–2016–79–5–29–32. 5. Khaliullin F. A., Samorodov A. V., Shabalina Yu.V., Kamilov F. Kh. Agent for treatment and prevention of thrombosis. Patent RU 2662308 C1. 25.07.2018. Bull. No 21. 10 pp. (In Russ.). 6. Kamilov F. Kh., Timirkhanova G.A., Samorodova A.I. et al. Antiaggregatory activity of new 1-ethylxanthine cyclohexylammonium salt in vitro. Kazanskij medicinskij zhurnal. 2013;94(5):692– 5. (In Russ.). 7. Vestrick R.J., Winn M.E., Eitzman D.T. Murine models of vascular thrombosis. Arterioscler Thromb Vasc Biol. 2007;27(10):2079– 93. DOI: 10.1161/ATVBAHA.107.142810. 8. Макаров В.А., Спасов А.А., Плотников М.Б. и др. Методические рекомендации по изучению лекарственных средств, влияющих на гемостаз. Тула: Гриф и К, 2012. 453–479. Makarov V.A., Spasov A.A., Plotnikov M.B. et al. Methodical recommendations for the study of drugs that affect hemostasis. Tula: Grif i K, 2012. 453–79. (In Russ.). 9. Khaliullin F. A., Shabalina Yu.V., Timirkhanova G. A. et al. 3-methyl-8-piperazino-7-(thietanyl-3)-1-ethylxanthine hydrochloride, exhibiting antiaggregant and disaggregation activity. Patent RU 2404181 C1. 20.11.2010. Bul. No 32. 5 pp. (In Russ.). 10. Di Minno G., Silver M.J., Murphy S. Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood. 1983;61(6):1081–5. 11. Саркисов Д.С., Перов Ю.Л. Микроскопическая техника: руководство для врачей и лаборантов. М.: Медицина, 1996. 544 с. Sarkisov D.S., Perov Yu.L. Microscopic technique: a guide for physicians and laboratory assistants. Moscow: Medicine, 1996. 544 рp. (In Russ.). 12. Wang H., Ye Y., Wang W. et al. Xinmailong modulates platelet function and inhibits thrombus formation via the platelet αIIbβ3-mediated signaling pathway. Front Pharmacol. 2019;10:1– 5. DOI: 10.3389/fphar.2019.00923. 13. Choi J.-H., Park S.-E., Kim S.-J., Kim S. Kaempferol inhibits thrombosis and platelet activation. Biochimie. 2015;115:177–86. DOI: 10.1016/j.biochi.2015.06.001. 14. Furie B., Furie B.C. Thrombus formation in a living mouse. Pathophysiol Haemost Thromb. 2006;35(1–2):1–4. DOI: 10.1159/000093534. 15. Chazova I.E., Oshepkova E.V., Zhernakova Yu.V. Diagnostics and treatment of arterial hypertension. Evrazijskij kardiologicheskij zhurnal. 2015;(2):3–30. (In Russ.). 16. Hagemeyer C.E., Peter K. Targeting the platelet integrin GPIIb/IIIa. Curr Pharm Des. 2010;16(37):4119–33. DOI: 10.2174/138161210794519255. 17. Giordano A., Musumeci G., D’Angelillo A. et al. Effects of glycoprotein IIb/IIIa antagonists: antiplatelet aggregation and beyond. Curr Drug Metab. 2016;17(2):194–203. DOI: 10.2174/138920021766 6151211121112.